At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 248 enrolled
Drug / intervention
Surufatinib +1 moredrug
Likely dose
Surufatinib 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-label, Single-arm, Multi-center Study of the Efficacy and Safety of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Surufatinib and Toripalimab for Advanced Solid Tumors. Completed, enrolled 248 participants across 2 sites.
Detailed Summary
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Surufatinib single agent or Surufatinib combined with Toripalimab in patients with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartDec 2019
Primary CompletionFeb 2023
TodayJul 2026
First PostedNov 20, 2019
Enrollment StartDec 26, 2019
Primary CompletionFeb 28, 2023
TodayJul 1, 2026
Enrollment to primary: 3.2 yearsPosted 6.6 years ago
Interventions
Surufatinibdrug
Surufatinib is a tablet in the form of 50mg, oral, once a day.
Toripalimabdrug
Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.